Brovana Related Published Studies
Well-designed clinical trials related to Brovana (Arformoterol Inhalation)
Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. [2007.02]
Well-designed clinical trials possibly related to Brovana (Arformoterol Inhalation)
Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids. [2008.09]
Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. [2008.05]
Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial. [2008.04]
Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. [2008.04]
Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. [2008.03]
Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? [2008.01]
Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. [2008]
Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma. [2007.11]
Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. [2007.11]
Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. [2007.10]
Effects of formoterol on exercise tolerance in severely disabled patients with COPD. [2007.10]
Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists. [2007.08]
Acute asthma intervention: insights from the STAY study. [2007.06]
A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. [2007.05]
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. [2007.03.06]
Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma. [2007.03]
The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. [2007.02]
Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. [2006.12.04]
The effect of formoterol inhalation on endurance performance in hypobaric conditions. [2006.12]
Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children. [2006.09]
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. [2006.08.26]
Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. [2006.07]
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. [2006.06]
Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. [2006.05]
Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. [2006.05]
Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. [2006.05]
Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. [2006.04]
Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. [2006.04]
Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. [2006.03]
Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. [2006.02]
Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. [2006.02]
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. [2006.01.24]
The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler. [2006.01]
Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. [2006]
Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients? [2006]
Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. [2006]
Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer. [2006]
Formoterol induces tolerance to the bronchodilating effect of Salbutamol following methacholine-provocation test in asthmatic children. [2006]
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. [2006]
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. [2005.09.16]
Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. [2005.09]
Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients. [2005.09]
Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. [2005.09]
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. [2005.08]
Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. [2005.06]
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. [2005.05]
The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. [2005.04]
Formoterol used as needed in patients with intermittent or mild persistent asthma. [2005.04]
Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. [2005.03]
Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain. [2005.01]
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. [2005]
Comparison of the bronchodilating effects of formoterol and albuterol delivered by hydrofluoroalkane pressurized metered-dose inhaler. [2005]
Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. [2004.10]
An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. [2004.10]
Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline. [2004.10]
Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. [2004.10]
Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. [2004.09]
Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction. [2004.09]
The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. [2004.08]
Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. [2004.08]
Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. [2004.05]
Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. [2004.05]
Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. [2004.03]
The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. [2004.03]
Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. [2004.02]
Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. [2004.02]
Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. [2004]
Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. [2004]
Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. [2004]
Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. [2004]
Ciclesonide. [2004]
Efficacy and tolerability of formoterol Turbuhaler in children. [2003.12]
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. [2003.12]
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. [2003.11]
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. [2003.11]
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. [2003.11]
Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. [2003.10]
Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. [2003.10]
Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. [2003.09]
Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. [2003.09]
Serious asthma exacerbations in asthmatics treated with high-dose formoterol. [2003.07]
One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. [2003.06]
An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. [2003.05.31]
Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. [2003.05]
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. [2003.05]
Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. [2003.04]
Effect of a long- and short-acting beta2-agonist on exercise-induced arterial hypoxemia. [2003.04]
An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. [2003.01]
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. [2003.01]
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. [2003.01]
Bronchodilating effects of cumulative doses of formoterol from a novel multi-dose inhaler (Airmax). [2003.01]
Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. [2003]
Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. [2003]
Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. [2003]
Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. [2003]
A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. [2002.12]
The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. [2002.12]
Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. [2002.10]
Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. [2002.09]
One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. [2002.08]
|
